- Trials with a EudraCT protocol (4,400)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,400 result(s) found for: - HIV Infection..
Displaying page 166 of 220.
EudraCT Number: 2008-006342-25 | Sponsor Protocol Number: HM08 / 8625 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:Leeds Teaching Hospitals NHS Trust | |||||||||||||
Full Title: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or withou... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023409-37 | Sponsor Protocol Number: AMLSG_15-10 | Start Date*: 2011-03-02 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM... | ||
Medical condition: Adult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001612-20 | Sponsor Protocol Number: ML21445 | Start Date*: 2008-05-29 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: A study of chlorambucil plus MabThera as induction therapy followed in responders by maintenance therapy versus observation on response rate in patients ≥ 60 years with previously untreated ... | |||||||||||||
Medical condition: CD20+ CLL, Binet stage C or Binet stages A-B | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002686-19 | Sponsor Protocol Number: HIPS-2013 | Start Date*: 2013-08-23 | |||||||||||
Sponsor Name:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano | |||||||||||||
Full Title: Hemophilia Inhibitor PUP Study - HIPS | |||||||||||||
Medical condition: Infants or children with severe haemophilia A previously untreated with factor concentrates. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000452-24 | Sponsor Protocol Number: M13-576 | Start Date*: 2017-03-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinic... | |||||||||||||
Medical condition: Hepatitis C Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001113-21 | Sponsor Protocol Number: NDPHRECOVERY | Start Date*: 2020-03-17 | ||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||
Full Title: Randomised Evaluation of COVID-19 Therapy (RECOVERY) | ||||||||||||||||||
Medical condition: COVID-19 (infection with SARS-CoV-2 virus) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005135-28 | Sponsor Protocol Number: 1184.13 | Start Date*: 2008-03-27 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co.KG | |||||||||||||
Full Title: A randomised, double–blind, crossover efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/ 25 µg) Inhalation Powder in the morning (PE Capsule via tiotropium/salmeterol HandiHaler®), Ti... | |||||||||||||
Medical condition: Patients of either sex, 40 years of age or older, and with a diagnosis of moderate to severe COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001563-29 | Sponsor Protocol Number: V72P4 | Start Date*: 2007-09-25 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Singl... | ||
Medical condition: no medical, condition; healthy, at risk volunteers will be recruited for a clinical trial to receive three vaccinations against meningococcal strain B and one vaccination against meningococcal stra... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011160-11 | Sponsor Protocol Number: GFM-Aza-Rev-09 | Start Date*: 2009-12-01 | |||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies (GFM) | |||||||||||||
Full Title: A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q | |||||||||||||
Medical condition: Myelodysplastic Syndrome(MDS) / Acute Myeloid Leukemia(AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004708-20 | Sponsor Protocol Number: RIFSYS | Start Date*: 2014-03-27 | ||||||||||||||||
Sponsor Name:King's College London [...] | ||||||||||||||||||
Full Title: A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients wi... | ||||||||||||||||||
Medical condition: Cirrhosis and chronic hepatic encephalopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000896-17 | Sponsor Protocol Number: SBP-9200-HBV-206 | Start Date*: 2019-05-20 |
Sponsor Name:Spring Bank Pharmaceuticals, Inc. | ||
Full Title: A PHASE 2, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC, HEPATITIS B e ANTIGEN NEGATIVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS AN... | ||
Medical condition: Chronic HBV-infected, HBeAg-negative subjects, who are non-cirrhotic and meet the cohort-specific criteria. Criteria for the planned cohorts are as follows: Cohort 1 Subjects who have been on NUC t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004457-40 | Sponsor Protocol Number: SL0023 | Start Date*: 2016-09-19 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY FOLLOWED BY AN OBSERVATIONAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SU... | |||||||||||||
Medical condition: SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) RO (Completed) HU (Completed) BG (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003479-22 | Sponsor Protocol Number: 200860 | Start Date*: 2016-11-09 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and development Ltd | |||||||||||||
Full Title: Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma | |||||||||||||
Medical condition: bronchial asthma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003591-37 | Sponsor Protocol Number: SPON846-10 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: Children with Eczema Antibiotic Management Study (CREAM) | |||||||||||||
Medical condition: Atopic Eczema | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016506-17 | Sponsor Protocol Number: OXYGEN-TIPO | Start Date*: 2010-04-20 | ||||||||||||||||||||||||||
Sponsor Name:U.O. Terapia intensiva | ||||||||||||||||||||||||||||
Full Title: RIGOROUS NORMOXYA MAINTENANCE IN INTENSIVE CARE UNIT: RANDOMIZED CONTROLLED TRIAL. | ||||||||||||||||||||||||||||
Medical condition: Critically ill patients because of chronic or acute respiratory, circulatory, neurologic, infective, metabolic, renal or hepatic pathologies. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020840-36 | Sponsor Protocol Number: V98_04 | Start Date*: 2011-08-08 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics GmbH | |||||||||||||
Full Title: A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent group B Streptococcus Vaccine in Healthy Pregnant Women | |||||||||||||
Medical condition: Invasive group B streptococcus disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004624-35 | Sponsor Protocol Number: GS39684 | Start Date*: 2017-05-10 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF GDC-0853 IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU) | |||||||||||||
Medical condition: Chronic spontaneous urticaria (CSU) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000041-14 | Sponsor Protocol Number: 269050-80-06-19 | Start Date*: 2020-06-19 | |||||||||||
Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005965-18 | Sponsor Protocol Number: ORL-CENS-2012 | Start Date*: 2012-02-21 | ||||||||||||||||||||||||||
Sponsor Name:Fundació Parc Taulí | ||||||||||||||||||||||||||||
Full Title: Open randomized trial to compare the bleeding during endoscopic nasal surgery after hypotensive anesthesia with clonidine or remifentanil. | ||||||||||||||||||||||||||||
Medical condition: Nasosinusal endoscopic surgery in patients with chronic sinusitis and/or nasal polyposis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000645-31 | Sponsor Protocol Number: 113264 | Start Date*: 2016-06-14 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase II, partially double-blind, randomised, controlled, single-centre study to assess the immunogenicity and reactogenicity of three different formulations of GSK Biologicals’ DTPw-HBV-IPV/Hib ... | |||||||||||||
Medical condition: Booster immunisation against poliomyelitis disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
